Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

. Here, to gain deeper insights into the aetiology of different brain diseases, we used specimens from 1,494 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex, comprising over 6.3 million individual nuclei. The cohort includes neurotypical controls, as well as donors affected by eight common and complex brain disorders: Alzheimer's disease (AD), diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson's disease (PD), tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder. We show that interindividual variation accounts for a substantial portion of gene expression variation. By comparing transcriptomic variation across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA processing and protein localization. After discounting these cross-disease signatures, we show stronger genetic and transcriptomic concordance among AD, DLBD, Vas and PD. Furthermore, we characterize transcriptomic variation among different AD phenotypes, distinct from those observed in healthy ageing, revealing a reduction in neuronal abundance in individuals with more severe AD, coupled with an increase in immune and vascular cell populations. Exploring the neuropsychiatric symptoms (NPSs) that frequently accompany AD, we find an increased abundance of deep-layer excitatory neurons associated with a broad range of NPSs. By constructing transcriptome trajectories that capture AD progression, we implicate cell-type-specific responses in the early and late stages of AD. Our disease atlas provides a perspective of the transcriptomic landscape in neurodegenerative and neuropsychiatric disorders, shedding light on shared and distinct processes involving the neurological-immune-vascular systems, and identifying potential targets for therapeutic intervention.

Key findings

Why it matters

This large single-cell atlas of the brain's prefrontal cortex compared gene activity across Alzheimer's and other brain disorders, finding that more severe Alzheimer's was tied to fewer neurons and more immune and vascular cells. It describes disease patterns rather than testing any treatment, so it does not show how to cure or prevent Alzheimer's.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature)
Journal's citation record 4 / 4 Nature: journal h-index 1,841 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 5 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.5 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 9.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Panos Roussos: h-index 94 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 12 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42778699)
Free to read 2 / 2 Free to read
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Lee, D., Koutrouli, M., Masse, N. Y., Hoffman, G. E., Kinrot, S., Wang, X., et al. (2026). Single-cell atlas of transcriptomic vulnerability across brain disorders. Nature. https://doi.org/10.1038/s41586-025-09573-z

Vancouver

Lee D, Koutrouli M, Masse NY, Hoffman GE, Kinrot S, Wang X, et al. Single-cell atlas of transcriptomic vulnerability across brain disorders. Nature. 2026. doi:10.1038/s41586-025-09573-z. PMID: 42778699.

BibTeX

@article{lee2026-42778699,
  author  = {Lee, Donghoon and Koutrouli, Mikaela and Masse, Nicolas Y. and Hoffman, Gabriel E. and Kinrot, Seon and Wang, Xinyi and Prashant, N. M. and Pjanic, Milos and others},
  title   = {{Single-cell atlas of transcriptomic vulnerability across brain disorders}},
  journal = {Nature},
  year    = {2026},
  doi     = {10.1038/s41586-025-09573-z},
  pmid    = {42778699},
  url     = {https://doi.org/10.1038/s41586-025-09573-z}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

In the news

1 news article on alzhub's news page cites this paper.

Related studies in Disease mechanisms

Also in Disease mechanisms

128 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →